Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Bodnar, Lubomir ^a   Stanczak, Aleksandra ^b   Cierniak, Szczepan ^a   Smoter, Marta ^a   Cichowicz, Marzena ^a   Kozlowski, Wojciech ^a   Szczylik, Cezary ^a   Wieczorek, Maciej ^b   Lamparska Przybysz, Monika ^b  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b Celon Pharma Ltd   (Poland)

Author keywords

catenin; Advanced ovarian cancer; E cadherin; Predictive marker; Prognostic marker; WNT 1

Indexed keywords

BETA CATENIN; CADHERIN; CDH1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; WNT1 PROTEIN; WNT1 PROTEIN, HUMAN;

AGED; BIOPSY; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; WNT SIGNALING PATHWAY;

AGED; BETA CATENIN; BIOPSY; CADHERINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; WNT SIGNALING PATHWAY; WNT1 PROTEIN;

EID: 84894492492     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-16     Document Type: Article

References (61)

1. Surface epithelial-stromal tumours. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J, Russell P, Buckley CH, Pisani P, Schwartz P, Goldgar DE, Silva E, Caduf R, Kubik-Huch RA, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs Lyon: IARCPress, Tavassoli FA, Devilee P, 2003 113 202
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer 2010 http://globocan.iarc.fr
3. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
4. Ovarian cancer management. Practice guidelines for nuclear physicians. Classe JM, Fontanelli R, Bischof-Delaloye A, Chatal JF, Q J Nucl Med Mol Imaging 2004 48 143 149 15243409 (Pubitemid 39248301)
5. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Aebi S, Castiglione M, ESMO Guidelines Working Group, Ann Oncol 2009 20 Suppl 4 21 23 19454452
6. The CA125 tumour associated antigen: a review of the literature. Jacobs I, Bast RC Jr, Hum Reprod 1989 4 1 12 10.1093/humrep/4.suppl-1.1 (Pubitemid 19069900)
7. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, McCready VR, Br J Obstet Gynaecol 1989 6 1395 1399 (Pubitemid 20020045)
8. Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R, Gynecol Oncol 1995 58 42 47 10.1006/gyno.1995.1181 7789889
9. The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ, Arch Gynecol Obstet 2011 284 221 227 10.1007/s00404-010-1655-2 20803207
10. The predictive and prognostic value of serum CA 125 halflife during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR, Gynecol Oncol 2004 93 131 136 10.1016/j.ygyno.2003.12.043 15047226 (Pubitemid 38429561)
11. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study. Riedinger JM, Eche N, Basuyau JP, Dalifard I, Hacene K, Pichon MF, Gynecol Oncol 2008 109 194 198 10.1016/j.ygyno.2008.01.035 18329083
12. WNT and beta-catenin signalling: diseases and therapies. Moon RT, Kohn AD, De Ferrari GV, Kaykas A, Nat Rev Genet 2004 5 691 701 10.1038/nrg1427 15372092 (Pubitemid 39150127)
13. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Gadducci A, Cosio S, Tana R, Genazzani AR, Crit Rev Oncol Hematol 2009 69 12 27 10.1016/j.critrevonc.2008.05.001 18595727
14. Wnt signaling in ovarian tumorigenesis. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF, Int J Gynecol Cancer 2008 18 954 962 10.1111/j.1525-1438.2007. 01127.x 17986238
15. Cadherin-catenin complex: protein interactions and their implications for cadherin function. Aberle H, Schwartz H, Kemler R, J Cell Biochem 1996 61 514 523 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R 8806074 (Pubitemid 26240128)
16. Wnt Homepage Stanford: The Nusse Laboratory, Stanford School of Medicine [ http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target-genes ]
17. The many ways of Wnt in cancer. Polakis P, Curr Opin Genet Dev 2007 17 45 51 10.1016/j.gde.2006.12.007 17208432 (Pubitemid 46109296)
18. Involvement of members of the cadherin superfamily in cancer. Berx G, van Roy F, Cold Spring Harb Perspect Biol 2009 1 003129 20457567
19. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Palacios J, Gamallo C, Cancer Res 1998 58 1344 1347 9537226 (Pubitemid 28193586)
20. beta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta catenin gene mutations, clinicopathological features, and clinical outcome. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A, Am J Pathol 1999 155 527 536 10.1016/S0002-9440(10)65148-6 10433945 (Pubitemid 29370402)
21. beta-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M, Chenevix-Trench G, Int J Cancer 1999 82 625 629 10.1002/(SICI)1097- 0215(19990827)82:5<625::AID-IJC1>3.0.CO;2-2 10417756 (Pubitemid 29356957)
22. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Davies BR, Worsley SD, Ponder BA, Histopathology 1998 32 69 80 10.1046/j.1365-2559.1998.00341.x 9522220 (Pubitemid 28122417)
23. Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I, Hum Pathol 2004 35 1469 1476 10.1016/j.humpath.2004.09.014 15619205 (Pubitemid 40017986)
24. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Sarrió D, Moreno-Bueno G, Sánchez-Estévez C, Bañón-Rodríguez I, Hernández-Cortés G, Hardisson D, Palacios J, Hum Pathol 2006 37 1042 1049 10.1016/j.humpath.2006.03.003 16867867 (Pubitemid 44080810)
25. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. Voutilainen KA, Anttila MA, Sillanpää SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM, J Clin Pathol 2006 59 460 467 10.1136/jcp.2005.029876 16461565
26. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Badiglian Filho L, Oshima CT, De Oliveira LF, De Oliveira CH, De Sousa DR, Gomes TS, Gonçalves WJ, Oncol Rep 2009 21 313 320 19148501
27. Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J, Mod Pathol 2010 23 113 122 10.1038/modpathol.2009.141 19820688
28. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS, Ann Oncol 2004 15 1535 1542 10.1093/annonc/mdh387 15367415 (Pubitemid 39409745)
29. Expression of E-cadherin and Ncadherin in surface epithelial stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Peralta-Soler A, Knudsen KA, Tecson-Miguel A, McBrearty FX, Han AC, Salazar H, Human Path 1997 28 734 739 10.1016/S0046-8177(97)90184-2 (Pubitemid 27258428)
30. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brännström M, Janson PO, Enerback S, Hedin L, Int J Cancer 1997 74 275 280 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.0.CO;2-W 9221804 (Pubitemid 27321795)
31. Constitutive and conditional cadherin expression in cultured human ovarian surface epithelium: influence of family history of ovarian cancer. Wong AS, Maines-Bandiera SL, Rosen B, Wheelock MJ, Johnson KR, Leung PC, Roskelley CD, Auersperg N, Int J Can 1999 81 180 188 10.1002/(SICI)1097-0215(19990412)81: 2<180::AID-IJC3>3.0.CO;2-7 (Pubitemid 29144744)
32. Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Sundfeldt K, Mol Cell Endocrinol 2003 202 89 96 10.1016/S0303-7207(03)00068-6 12770736 (Pubitemid 36593398)
33. E-Cadherin complex protein expression and survival in ovarian carcinoma. Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A, Gynecol Oncol 2000 79 362 371 10.1006/gyno.2000.5964 11104606
34. Symptomatology of ovarian cancer. Flam F, Einhorn N, Sjövall K, Eur J Obstet Gynecol Reprod Biol 1988 27 53 57 10.1016/S0028-2243(88)80010-8 3338609
35. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V, J Pathol 2000 192 460 469 10.1002/1096-9896(2000)9999:9999<:: AID-PATH726>3.0.CO;2-M 11113863
36. Ovarian cancer metastasis: integrating insights from disparate model organisms. Naora H, Montell DJ, Nat Rev Cancer 2005 5 355 366 10.1038/nrc1611 15864277 (Pubitemid 40637827)
37. Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions. Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. Pece S, Chiariello M, Murga C, Gutkind JS, J Biol Chem 1999 274 19347 19351 10.1074/jbc.274.27.19347 10383446 (Pubitemid 29314140)
38. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells. Reddy P, Liu L, Ren C, Lindgren P, Boman K, Shen Y, Lundin E, Ottander U, Rytinki M, Liu K, Mol Endocrinol 2005 19 2564 2578 10.1210/me.2004-0342 15928314 (Pubitemid 41362669)
39. E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A, Oncogene 2009 28 1206 1217 10.1038/onc.2008.470 19151754
40. Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells. Wang J, Zhou D, He X, Wang Y, Hu W, Jiang L, Dou J, Cell Mol Biol (Noisy-le-grand) 2011 57 Suppl L1606 OL1613
41. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH, Gastroenterology 2006 131 1486 1500 10.1053/j.gastro.2006.08.041 17101323 (Pubitemid 44708942)
42. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, et al. Cancer Gene Ther 2009 16 351 361 10.1038/cgt.2008.78 18949017
43. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Teng Y, Wang X, Wang Y, Ma D, Biochem Biophys Res Commun 2010 392 373 379 10.1016/j.bbrc.2010.01.028 20074550
44. Expression of Wnt-1, beta-catenin and c-myc in ovarian epithelial tumor and its implication. Xiao L, Zhuo-ying H, Chin J Cancer Res 2008 20 73 76 10.1007/s11670-008-0073-5 (Pubitemid 351428231)
45. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Peng C, Zhang X, Yu H, Wu D, Zheng J, Int J Gynecol Cancer 2011 21 280 288 10.1097/IGC.0b013e31820aaadb 21270611
46. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA 2nd, McAsey ME, Sugino N, Brard L, Watabe K, Hayashi K, Mol Cancer Res 2012 10 469 482 10.1158/1541-7786.MCR-11-0177 22232518
47. Wnt and calcium signaling: beta-catenin-independent pathways. Kohn AD, Moon RT, Cell Calcium 2012 38 439 446
48. Planar cell polarity signaling: a common mechanism for cellular polarization. Jenny A, Mlodzik M, Mt Sinai J Med 2006 73 738 750 17008934 (Pubitemid 44445777)
49. Selective activation mechanisms of Wnt signaling pathways. Kikuchi A, Yamamoto H, Sato A, Trends Cell Biol 2009 19 119 129 10.1016/j.tcb.2009.01.003 19208479
50. Genetic analysis of early- versus late-stage ovarian tumors. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI, Cancer Res 2001 61 5895 5904 11479231 (Pubitemid 32769109)
51. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, Lee J, Lillie J, Smith DI, Cancer Res 2002 62 262 270 11782386 (Pubitemid 34074013)
52. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ, Cancer Res 2003 9 1420 1426 (Pubitemid 36418396)
53. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE, Gynecol Oncol 2003 88 73 79 10.1006/gyno.2002.6851 12504632 (Pubitemid 36062670)
54. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG, Br J Cancer 2008 99 341 349 10.1038/sj.bjc.6604471 18628764
55. β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, Schaller M, Garbe C, Schittek B, PLoS One 2011 6 23429 10.1371/journal.pone.0023429 21858114
56. Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells: a link between beta-catenin/plakoglobin ratio and cisplatin resistance. Cimbora-Zovko T, Ambriović-Ristov A, Loncarek J, Osmak M, Eur J Pharmacol 2007 558 27 36 10.1016/j.ejphar.2006.11.077 17234182 (Pubitemid 46328882)
57. Cell and environment interactions in tumor microregions: the multicell spheroid model. Sutherland RM, Science 1988 240 177 184 10.1126/science.2451290 2451290
58. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin, Cancer Cell PJ 2003 3 377 386 10.1016/S1535-6108(03)00058-8 (Pubitemid 38340306)
59. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Li J, Wood WH 3rd, Becker KG, Weeraratna AT, Morin PJ, Oncogene 2007 26 2860 2872 10.1038/sj.onc.1210086 17072341 (Pubitemid 46701436)
60. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Kim CJ, Lee JW, Choi JJ, Choi HY, Park YA, Jeon HK, Sung CO, Song SY, Lee YY, Choi CH, Kim TJ, Lee JH, Kim BG, Bae DS, Eur J Cancer 2011 47 918 925 10.1016/j.ejca.2010.11.007 21134740
61. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B, OMICS 2009 13 345 354 10.1089/omi.2009.0008 19422301